GLP-1 and the Neurobiology of Eating Control: Recent Advances
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index; 82 of the 214 sources its claims cite were checked for support.
Abstract
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterized by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening. However, the field of obesity pharmacotherapy has now entered a new era of AOMs based on analogues of the gut hormone and neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions of these drugs elicit unprecedented levels of weight loss in clinical trials, which are now starting to be substantiated in real-world usage. Notably, these drugs reduce weight primarily by reducing energy intake, via activation of the GLP-1 receptor on multiple sites of action primarily in the central nervous system, although the most relevant sites of action, and the neural circuits recruited remain contentious. Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
Overview
CoChat Summary
TL;DR
This review synthesizes recent advances in GLP-1 neurobiology and obesity pharmacotherapy, arguing that GLP-1-based anti-obesity medications reduce eating mainly through CNS GLP-1R populations while endogenous peripheral and central GLP-1 systems are functionally separable. It highlights unresolved questions about the sites of action, nausea versus satiety circuits, real-world efficacy, and weight regain.
Key findings
- GLP-1-based AOMs reduce weight primarily by lowering energy intake via GLP-1R activation, mainly in the CNS; semaglutide achieved up to 15% weight loss in trials, while tirzepatide and retatrutide achieved placebo-subtracted weight loss of ≥20%, and CagriSema ∼15% in shorter-term phase 1/2 trials.
- Endogenous gut-derived GLP-1 contributes to satiation mainly through peripheral vagal afferents in the hepatic portal vein and intestinal mucosa, and via the ileal brake circuit; central NTS preproglucagon neurons mediate physiological satiation and stress-induced hypophagia but are not required for liraglutide or semaglutide anorectic effects.
- Recent rodent studies implicate multiple CNS GLP-1R populations in GLP-1RA effects, including the area postrema/NTS, locus coeruleus, hypothalamic arcuate and dorsomedial nuclei, and lateral septum; area postrema GLP-1R neurons may drive nausea, whereas NTS populations may mediate satiety, and tirzepatide’s lower discontinuation-inducing GI events may involve GIPR-expressing GABAergic area postrema neurons.
- Clinical limitations remain: real-world semaglutide weight loss ranges from 4% to 5% in one study to 13.4% in another; SELECT reported 8.7% placebo-subtracted weight loss at 4 years versus 12.5% in STEP 1 at 68 weeks; 10% to 15% of STEP/SURMOUNT participants were nonresponders, 32% in SELECT, and 19% in a real-world setting; GI side effects affect 50% to 60%, with discontinuation in 4% to 10%, and 50% to 65% of lost weight is regained up to a year after semaglutide or tirzepatide cessation.
Methods
- Targeted narrative synthesis of recent developments in GLP-1 neurobiology relevant to obesity, highlighting studies on how GLP-1 signaling modulates eating and identifying open questions for GLP-1-based AOMs.
- Includes discussion of rodent mechanistic studies and a table summarizing key body weight loss efficacy from clinical trials versus real-world studies of GLP-1RAs licensed for obesity.
- No primary experimental data, systematic search strategy, or meta-analytic methods are reported.
Limitations
- The paper states that the most relevant sites of action and neural circuits recruited by GLP-1RAs remain contentious, and that many mechanistic insights come from rodent studies.
- It notes that real-world effectiveness data are conflicting and that clinical trials tend to overestimate weight loss, with limited long-term data for newer GLP-1RA-based combination therapies.
- Evident from the text: as a narrative review, it does not report a systematic search strategy or formal risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
29 Valid · 5 Not valid · 59 Not checked · 10 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Local injection of GLP-1 and/or GLP-1R agonists (GLP-1RAs) elicits anorectic effects in virtually all GLP-1R-expressing CNS regions investigated (reviewed in (15, 16)).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Central GLP-1 System Targets of Endogenous GLP-1 and GLP-1RA Anti-Obesity Medications
What the sources say
- Partly supportedcites [15] McLean, 2021, Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation, Endocr Rev sourceExperimental — accuracy not yet measured
The review reports that intracerebroventricular GLP-1 injection causes hypophagia (GLP-1 receptors within the nervous system, p. 26) and discusses anorectic effects involving particular CNS regions, including the ARC (GLP-1Rs in circumventricular organs, p. 29). It does not establish that local injections elicit anorectic effects in virtually all GLP-1R-expressing CNS regions investigated. (LLM, conf=0.82)
- Disputedcites [16] Trapp, 2022, Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment, Br J Pharmacol sourceExperimental — accuracy not yet measured
The review reports that direct CNS injection of GLP-1 or its receptor agonists can reduce food intake. But in “What are the roles of brain-derived GLP-1,” it emphasizes region-specific effects: GLP-1 microinjection into the central amygdala elicited conditioned taste aversion, not hypophagia. That finding runs against the claim that local injection is anorectic in virtually all investigated regions. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The density of L-cells increases toward the distal end of the gastrointestinal tract, peaking in the ileum and colon—a paradoxical observation given that nutrient-sensing cell density would be expected to be highest in the proximal intestine where nutrient absorption primarily takes place (25, 33).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Not checked yetcites [25] Gribble, 2021, Metabolic messengers: glucagon-like peptide 1, Nat Metab source
- Supportedcites [33] Lewis, 2020, Selective stimulation of colonic L cells improves metabolic outcomes in mice, Diabetologia source
The Introduction (p.1 of our copy) states that GLP-1 is produced 'alongside another proglucagon product GLP-2 in increasing amounts in the distal gut, where it is co-stored and released with... Peptide YY (PYY)', and that 'the distal gut harbours the majority of endogenous GLP-1 and PYY stores and recruiting this L-cell population could be developed as a therapeutic strategy'. The same Introduction uses 'distal gut' for the ileum and colon ('When Gcg was deleted only from the ileum and colon... suggesting a greater contribution of the distal gut'), so the caudal gradient peaking in ileum/colon is what our copy conveys. The source frames it as hormone content/L-cell population in mice rather than a counted cell density, and the adjacent passage ('As most nutrient absorption occurs in the proximal small intestine...') supplies the paradox framing the citing sentence adds. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, rather than acting via the canonical mechanosensory VAN pathway (23), ileal GLP-1-evoked gastric distension suppressed eating via a spinal afferent pathway to the parasubthalamic nucleus and a brainstem premotor circuit controlling orofacial food rejection behavior.”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [44] Zhang, 2022, An inter-organ neural circuit for appetite suppression, Cell source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [23] Brierley, 2021, Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating, Br J Pharmacol source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This intestinofugal pathway connects GLP-1R-expressing enteric neurons to stomach-innervating sympathetic neurons which inhibit gastric emptying and eating by a potent nitric oxide neuron-mediated increase in gastric distension.”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [44] Zhang, 2022, An inter-organ neural circuit for appetite suppression, Cell source
The RESULTS sections state each element of the attributed circuit: GLP-1R+ ileal myenteric/intestinofugal neurons project to and activate abdominal sympathetic (celiac) ganglia, and IFNs act on the stomach by recruiting stomach-innervating noradrenergic CG neurons (CGNA–Stom) (RESULTS, 'Ileal intestinofugal myenteric neurons express GLP-1R...' and 'Intestinal GLP-1 controls the stomach via abdominal sympathetic ganglia'). CGNA–Stom preferentially and densely target inhibitory Nos1 gastric neurons, whose activation causes marked gastric distension, inhibits gastric contractions and halves eating, while Nos1Stom ablation abolishes GLP-1ii-induced distension and anorexia (RESULTS, 'Intestinal GLP-1 controls appetite and stomach distension via nitric oxide gastric neurons'; 'Chemical activation of nitric oxide gastric neurons mimics intestinal GLP-1'). The DISCUSSION summarises this as ileal GLP-1 causing anorexia and stomach distension via intestinofugal-mediated sympathetic reflexes that activate gastric nitric oxide neurons, and the abstract's ~100% gastric volume enlargement supports 'potent'. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [47] Huang, 2024, Dissociable hindbrain GLP1R circuits for satiety and aversion, Nature source
The cited sentence attaches this source (refs 47–49) to the area postrema and nucleus tractus solitarius as sites of direct action of GLP-1-based drugs on eating and body weight, and our copy states exactly that: 'Obesity drugs act on hindbrain GLP1R neurons' reports that peripherally-delivered GLP1-based obesity drugs directly target hindbrain DVC neurons and that DVCGLP1R ablation blocked exendin-4 and semaglutide-induced anorexia and semaglutide-induced weight loss in obese mice, highlighting 'the DVC as a critical site of action'. The Abstract and 'In vivo activity in APGLP1R and NTSGLP1R neurons' section further dissociate the two subregions (NTSGLP1R activation drives satiety, APGLP1R activation drives aversion with reduced intake), supporting the paraphrase's 'putative' framing. The other sites listed in the sentence (locus coeruleus, arcuate, dorsomedial hypothalamus, lateral septum) are credited to separate citations (50–54) and are not part of what this source is offered for; our copy does not address LC, DMH or lateral septum, and it actually finds ARC GLP1R neurons dispensable for drug efficacy. (LLM, conf=0.85)
- Partly supportedcites [48] Zhang, 2021, Area postrema cell types that mediate nausea-associated behaviors, Neuron sourceExperimental — accuracy not yet measured
Our copy supports the area postrema as a direct, rodent-established site of GLP-1-agonist action: the Results section 'Area postrema GLP1R neurons condition flavor avoidance to peripheral poisons' shows exendin-4 acts through GLP1R in the caudal brainstem (region-specific knockout/rescue in AP, not vagal GLP1R), and the AP cell atlas documents Glp1r-expressing neuron clusters. But the effect this source attributes to AP GLP1R neurons is nausea-like aversion, not the effects on eating and body weight the citing sentence claims: the same Results passage states 'exendin-4 still decreased food intake in Glp1r-ABLATEAP mice... suggesting that at least partially distinct neural circuits mediate GLP1R-evoked appetite suppression and nausea,' and the Discussion assigns feeding inhibition to GLP1R neurons in several brain regions (crediting Adams et al. 2018, Burmeister et al. 2017, Fortin et al. 2020, Ghosal et al. 2017, Secher et al. 2014) while aversion is 'a more focal brainstem response.' NTS appears only as a site of Glp1r expression/co-recorded neurons, not as a demonstrated site of action for eating or weight. (LLM, conf=0.78)
- Not checked yetcites [49] Fortin, 2020, GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats, Sci Transl Med source
- Supportedcites [50] Fortin, 2023, The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1, Sci Adv source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [51] Secher, 2014, The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss, J Clin Invest source
The Discussion states that peripherally injected liraglutide targets hypothalamic GLP-1Rs on ARC neurons, which bind and internalize the drug, respond electrophysiologically to GLP-1, and whose local GLP-1R blockade attenuates liraglutide-induced weight loss (Discussion, p. n/a). The Introduction/abstract confirms the rodent (rat and mouse) mechanistic design and that ARC uptake is GLP-1R dependent, while the conclusion attributes the weight-lowering mode of action to direct activation of CART/POMC neurons in the ARC. Thus this paper does identify the hypothalamic arcuate nucleus as a site of direct action putatively mediating a GLP-1-based anti-obesity medication's effects on eating and body weight, exactly the part of the sentence carried by citations 51-52. (LLM, conf=0.90)
- Partly supportedcites [52] Imbernon, 2022, Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions, Cell Metab sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
46 more claims · 12 with their cited sources checked
Create a free account to see all 103 claims and to verify the 132 references still open.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 15–25 % weight loss over 12–24 months”
From Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Gastrointestinal side effects are typically classed as mild or moderate, and reported to subside in most patients following titration up to maintenance doses (77, 79, 104), although they still lead to permanent discontinuation of treatment in 4% to 10% of participants (77, 79, 95).”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“The loss of lean body mass is another common side effect of GLP-1RAs, with studies reporting that lean mass loss accounts for ∼ 45% and ∼ 25% of total loss for semaglutide (79, 105) and tirzepatide (98), respectively.”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544 · cited 1×
“…by a transition from underweight to obesity as the most prevalent form of malnutrition in almost all countries, with more than 1 billion people now living with obesity due to the worldwide prevalence doubling in men, tripling in women, and quadrupling in children over the last 30 years (6, 7).”
Body-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“…starting weight/BMI or with prior exposure to GLP-1RAs (95, 102), and it is reduced by a third in type 2 diabetics and in male individuals (79, 93, 95–97 , In summary, while the newer GLP-1RAs represents a step change in AOM efficacy, many underserved patient populations remain, and thus…”
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“Early human studies, using intravenously infused physiological concentrations of the active form of the GLP-1 peptide (7-36 amide; see (14) for details of post-translational processing of glucagon gene products), reported reduced appetite and food intake (26, 27).”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 2×
“…multi-agonists, such as tirzepatide (co-agonist of GLP-1R and glucose-dependent in-sulinotropic polypeptide receptor [GIPR]), and retatrutide (tri-agonist of GLP-1R, GIPR, and glucagon receptor), are achieving unprecedented placebo-subtracted weight loss of ≥ 20% in clinical trials (80, 81).”
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“That this phenomena occurs is certainly supported by evidence from clinical trials, with reports that 50% to 65% of total weight loss is regained up to a year after semaglutide or tirzepatide cessation (100, 121, 122).”
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 2×
“…beyond headline weight loss results, substantial response variability exists within patient populations, with the STEP and SURMOUNT trials reporting that 10% to 15% of individuals lose 5% on semaglutide or tirzepatide, respectively, and are thus classed as “nonresponders” (77, 79, 80, 94, 100).”
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 4×
“%) and side effects which are compliance-limiting, and in some cases life-threatening (13).”
InfluentialThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“That this phenomena occurs is certainly supported by evidence from clinical trials, with reports that 50% to 65% of total weight loss is regained up to a year after semaglutide or tirzepatide cessation (100, 121, 122).”
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“Similarly, global GLP-1R knockout mice did not show altered food intake or body weight (30, 31), consistent with results from mice with GLP-1R knockout targeted to discrete domains of peripheral, central and enteric nervous systems (32).”
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“It is well-established, however, that GLP-1RAs activate neurons in the AP and the NTS (22, 63) and induce differential gene expression in the AP (63, 107), findings relevant because of the well-established role of the AP in sensing nausea-inducing stimuli (48, 108).”
Tomiyama, A. J. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102936 · Cited by 695 · cited 1×
“…popular culture that obesity is simply a failure of willpower, rather than a chronic disease requiring personalized and often long-term treatment (11, 123), given that similar criticisms are not typically leveled at other lifelong treatments for chronic disease, such as insulin for type 1 diabetes.”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Sensory neurons that detect stretch and nutrients in the digestive system
Williams, E. K., Chang, R. B., Strochlic, D. E., Umans, B. D., Lowell, B. B., & Liberles, S. D. (2016) · Cell · doi:10.1016/j.cell.2016.05.011 · Cited by 645 · cited 2×
“Studies combining anatomical tracing with single cell transcriptomics suggest that a substantial proportion of GLP-1R-expressing vagal afferent neurons (VANs) innervate the HPV, but relatively few innervate intestinal villi (36–38).”
Verdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Genetic identification of vagal sensory neurons that control feeding
Bai, L., Mesgarzadeh, S., Ramesh, K. S., Huey, E. L., Liu, Y., Gray, L. A., Aitken, T. J., Chen, Y., Beutler, L. R., Ahn, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.031 · Cited by 494 · cited 3×
“…likely comes from oxytocin receptor-expressing VANs, a mechanosensory vagal population largely distinct from GLP-1R-expressing VANs, which preferentially innervate the duodenum rather than stomach, consistent with the role of PPGs in mediating large meal-induced satiation (22, 23, 36, 57).”
NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-pandemic Data Files
Bryan, S., Afful, J., Carroll, M., Te-Ching, C., Orlando, D., Fink, S., & Fryar, C. (2021) · doi:10.15620/cdc:106273 · Cited by 479
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478 · cited 1×
“Maintenance therapy using orally active formulations of GLP-1RAs such as Rybelsus (oral sema-glutide) (129); or the small molecule GLP-1R partial agonist orforglipron (130) may also represent a viable strategy.”
Ileal brake: a sensible food target for appetite control. A review
Maljaars, P. W. J., Peters, H. P. F., Mela, D. J., & Masclee, A. A. M. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.07.018 · Cited by 451 · cited 1×
“This visceral alarm reflex potently inhibits eating and gastrointestinal motility upon detection of malabsorbed nutrients or bile salts in the distal intestine, which can occur after rapidly consumed large meals or conditions of potentiated gastric emptying (14, 43).”
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442 · cited 2×
“To counteract this, recent GLP-1-based AOM trials, such as STEP 5 and SURMOUNT 3 (77, 81), implemented intention-to-treat methods such as co-primary endpoints ( ≥ 5% baseline weight loss outcome, and significant placebo-subtracted weight loss) and treatment-focused estimands from all randomized…”
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · cited 5×
“Key drivers identified for reduced adherence to GLP-1RAs are decreasing BMI class (95), and common adverse effects of nausea, emesis, and diarrhea, which affect ∼ 60% of patients (17).”
InfluentialIs 5% weight loss a satisfactory criterion to define clinically significant weight loss?
Williamson, D. A., Bray, G. A., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21358 · Cited by 367
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · cited 15×
“The NTS population may only be partially accessible to peripherally administered GLP-1RAs (16, 64), and GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
InfluentialJacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Verdich, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 336
Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334 · cited 1×
“Other combinations, such as semaglutide with the amylin analogue cagrilintide (CagriSema), are showing great promise, achieving ∼ 15% body weight loss in shorter-term phase 1 and 2 clinical trials (82, 83).”
Vagal neurocircuitry and its influence on gastric motility
Travagli, R. A., & Anselmi, L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.76 · Cited by 323
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“Other combinations, such as semaglutide with the amylin analogue cagrilintide (CagriSema), are showing great promise, achieving ∼ 15% body weight loss in shorter-term phase 1 and 2 clinical trials (82, 83).”
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 6×
“Notably, this drug class reduces weight primarily by reducing energy intake, via activation of the cognate GLP-1 receptor (GLP-1R), mainly on sites of action in the central nervous system (CNS) (15, 16).”
InfluentialKnockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269 · cited 2×
“Given the role of GLP-1R-expressing VANs in physiological satiation (23, 39), reduced gut GLP-1 secretion and/or decreased vagal sensitivity to GLP-1 could conceivably be part of a vagal contribution to the impaired satiation reported in people living with obesity (135).”
Central and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
Self-citationArea postrema cell types that mediate nausea-associated behaviors
Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.010 · Cited by 263 · cited 4×
“GLP-1R neurons in both the NTS and AP exhibit substantial molecular heterogeneity, including in cell surface receptor expression (48, 107, 118, 119).”
InfluentialZhong, W., Shahbaz, O., Teskey, G., Beever, A., Kachour, N., Venketaraman, V., & Darmani, N. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115797 · Cited by 253
20 YEARS OF LEPTIN: Role of leptin in energy homeostasis in humans
Rosenbaum, M., & Leibel, R. L. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0358 · Cited by 248
Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus
Rinaman, L. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.2.r582 · Cited by 244
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s008 · Cited by 244 · cited 1×
“Prior to the 2014 approval of 3-mg liraglutide for this indication (70), most AOMs barely achieved the ≥ 5% threshold for clinically meaningful weight loss (71–73).”
Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity
Sen, T., Cawthon, C. R., Ihde, B. T., Hajnal, A., DiLorenzo, P. M., de La Serre, C. B., & Czaja, K. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.027 · Cited by 239
Acosta, A., Camilleri, M., Abu Dayyeh, B., Calderon, G., Gonzalez, D., McRae, A., Rossini, W., Singh, S., Burton, D., & Clark, M. M. (2021) · Obesity · doi:10.1002/oby.23120 · Cited by 222 · cited 1×
“A likely contributing factor for this is the heterogeneity of obesity, with previous studies demonstrating that tailoring obesity treatments to obesity phenotypes significantly improves weight-loss outcomes (101).”
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00966-w · Cited by 218 · cited 1×
“Maritide, the GIPR antagonist/GLP-1RA, resulted in ∼ 16% body weight loss that was maintained up to a 70% level (hence just 30% of lost weight regained) for 5 months after just 3 monthly doses (128), suggesting potential for maintenance therapy with infrequent dosing.”
Holt, M. K., Richards, J. E., Cook, D. R., Brierley, D. I., Williams, D. L., Reimann, F., Gribble, F. M., & Trapp, S. (2019) · Diabetes · doi:10.2337/db18-0729 · Cited by 212 · cited 2×
“…likely comes from oxytocin receptor-expressing VANs, a mechanosensory vagal population largely distinct from GLP-1R-expressing VANs, which preferentially innervate the duodenum rather than stomach, consistent with the role of PPGs in mediating large meal-induced satiation (22, 23, 36, 57).”
Self-citationJensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207 · cited 1×
“Supplementing GLP-1-based treatments with lifestyle change has been investigated as a possible long-term strategy to ameliorate weight regain, with some studies demonstrating enhanced weight loss and reduced weight regain following cessation of GLP-1RA-based therapies (100, 125).”
Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 1×
“…that the GLP-1R/GIPR co-agonist tirzepatide elicits fewer discontinuation-inducing adverse gastrointestinal events than semaglutide (98, 99), likely in part due to GIPR-expressing GABAergic AP neurons inhibiting AP and/or NTS neurocircuits which mediate GLP-1RA-induced nausea (114, 116, 117).”
Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194 · cited 1×
“The widespread projection pattern of PPGs is largely mirrored by the distribution of GLP-1R-expressing neurons, found in virtually all CNS regions implicated in the control of eating and energy balance (20, 45).”
An inter-organ neural circuit for appetite suppression
Zhang, T., Perkins, M. H., Chang, H., Han, W., & de Araujo, I. E. (2022) · Cell · doi:10.1016/j.cell.2022.05.007 · Cited by 192 · cited 1×
“A recent study by Zhang et al (44) elegantly delineated the neural circuit basis for this ileal brake, mapping a GLP-1-dependent inter-organ circuit from ileal L-cells to the brain.”
Western diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 191
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186
A genetic map of the mouse dorsal vagal complex and its role in obesity
Ludwig, M. Q., Cheng, W., Gordian, D., Lee, J., Paulsen, S. J., Hansen, S. N., Egerod, K. L., Barkholt, P., Rhodes, C. J., Secher, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00363-1 · Cited by 186 · cited 3×
“GLP-1R neurons in both the NTS and AP exhibit substantial molecular heterogeneity, including in cell surface receptor expression (48, 107, 118, 119).”
McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia · doi:10.1007/s00125-019-05065-8 · Cited by 184 · cited 1×
“The loss of lean body mass is another common side effect of GLP-1RAs, with studies reporting that lean mass loss accounts for ∼ 45% and ∼ 25% of total loss for semaglutide (79, 105) and tirzepatide (98), respectively.”
Hsu, T. M., Hahn, J. D., Konanur, V. R., Lam, A., & Kanoski, S. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.175 · Cited by 176
European Commission classifies obesity as a chronic disease
Burki, T. K. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00145-5 · Cited by 174
Richard, J. E., Anderberg, R. H., Göteson, A., Gribble, F. M., Reimann, F., & Skibicka, K. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119034 · Cited by 168 · cited 1×
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109–113).”
The physiological control of eating: signals, neurons, and networks
Watts, A. G., Kanoski, S. E., Sanchez-Watts, G., & Langhans, W. (2022) · Physiological Reviews · doi:10.1152/physrev.00028.2020 · Cited by 168 · cited 1×
“Thus, gut-derived GLP-1 most likely contributes to the process of satiation by acting peripherally as an interoceptive input to central eating control networks (41), and/or by more directly slowing gastric emptying via vago-vagal circuitry (42).”
Dissociable hindbrain GLP1R circuits for satiety and aversion
Huang, K.-P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T., Hanchak, N. D., Patel, N., Gbenou, Y. S. K., Adriaenssens, A. E., et al. (2024) · Nature · doi:10.1038/s41586-024-07685-6 · Cited by 166 · cited 3×
“Indeed, a recent rodent study has posited the AP and NTS as indispensable targets for the anorectic and weight loss effects of semaglutide, and that GLP-1R neurons in the AP, but not NTS, drive GLP-1RA-mediated nausea responses (47).”
Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P. (2018) · Diabetes · doi:10.2337/db17-1385 · Cited by 159
Alcantara, I. C., Tapia, A. P. M., Aponte, Y., & Krashes, M. J. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00611-y · Cited by 155
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154 · cited 17×
“The NTS population may only be partially accessible to peripherally administered GLP-1RAs (16, 64), and GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
InfluentialSelf-citationGLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim, K. S., Park, J. S., Hwang, E., Park, M. J., Shin, H. Y., Lee, Y. H., Kim, K. M., Gautron, L., Godschall, E., Portillo, B., et al. (2024) · Science · doi:10.1126/science.adj2537 · Cited by 148
PRL-releasing peptide reduces food intake and may mediate satiety signaling
Lawrence, C. B., Ellacott, K. L. J., & Luckman, S. M. (2002) · Endocrinology · doi:10.1210/endo.143.2.8609 · Cited by 147 · cited 1×
“…in the AP are a heterogeneous population, with subsets co-expressing Gfral (48, 107), encoding the GDF15 receptor known to be involved in the neural circuitry for nausea (114), or Prlhr , encoding the receptor for prolactin-releasing peptide hormone shown to mediate satiety without aversion (115).”
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140 · cited 1×
“However, there is conflicting evidence from mechanistic studies manipulating endogenous peripheral GLP-1 signaling in rodents, with reports of impaired glucose handling, but no effect on cumulative food intake or body weight, following deletion of the glucagon gene from L-cells (28, 29).”
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 140
Self-citationFortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125 · cited 13×
“Studies combining anatomical tracing with single cell transcriptomics suggest that a substantial proportion of GLP-1R-expressing vagal afferent neurons (VANs) innervate the HPV, but relatively few innervate intestinal villi (36–38).”
InfluentialTanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124
Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · cited 2×
“Similarly, global GLP-1R knockout mice did not show altered food intake or body weight (30, 31), consistent with results from mice with GLP-1R knockout targeted to discrete domains of peripheral, central and enteric nervous systems (32).”
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Dowsett, G. K. C., Lam, B. Y. H., Tadross, J. A., Cimino, I., Rimmington, D., Coll, A. P., Polex-Wolf, J., Knudsen, L. B., Pyke, C., & Yeo, G. S. H. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101240 · Cited by 98
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Salinas, C. B. G., Lu, T. T.-H., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A. J., Cornea, A., Conradsen, K., Hecksher-Sørensen, J., Dahl, A. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28496-6 · Cited by 95
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
Self-citationKrieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
Sequential appetite suppression by oral and visceral feedback to the brainstem
Ly, T., Oh, J. Y., Sivakumar, N., Shehata, S., La Santa Medina, N., Huang, H., Liu, Z., Fang, W., Barnes, C., Dundar, N., et al. (2023) · Nature · doi:10.1038/s41586-023-06758-2 · Cited by 90
GLP-1-directed NMDA receptor antagonism for obesity treatment
Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea-Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J., Breum, A. W., et al. (2024) · Nature · doi:10.1038/s41586-024-07419-8 · Cited by 89
On the pathogenesis of obesity: causal models and missing pieces of the puzzle
Magkos, F., Sørensen, T. I. A., Raubenheimer, D., Dhurandhar, N. V., Loos, R. J. F., Bosy‐Westphal, A., Clemmensen, C., Hjorth, M. F., Allison, D. B., Taubes, G., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01106-8 · Cited by 87
Costa, A., Ai, M., Nunn, N., Culotta, I., Hunter, J., Boudjadja, M. B., Valencia-Torres, L., Aviello, G., Hodson, D. J., Snider, B. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101407 · Cited by 79
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity · doi:10.1002/oby.22462 · Cited by 77
Adriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
Self-citationWhat is GLP-1 really doing in obesity?
Hira, T., Pinyo, J., & Hara, H. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.09.003 · Cited by 74 · cited 1×
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132–134).”
A brainstem circuit for nausea suppression
Zhang, C., Vincelette, L. K., Reimann, F., & Liberles, S. D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110953 · Cited by 68
Panaro, B. L., Yusta, B., Matthews, D., Koehler, J. A., Song, Y., Sandoval, D. A., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100990 · Cited by 67 · cited 7×
“However, there is conflicting evidence from mechanistic studies manipulating endogenous peripheral GLP-1 signaling in rodents, with reports of impaired glucose handling, but no effect on cumulative food intake or body weight, following deletion of the glucagon gene from L-cells (28, 29).”
InfluentialMatikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63 · cited 1×
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132–134).”
Differential mechanisms affecting weight loss and weight loss maintenance
Rosenbaum, M., & Foster, G. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00864-1 · Cited by 61
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59
Selective stimulation of colonic L cells improves metabolic outcomes in mice
Lewis, J. E., Miedzybrodzka, E. L., Foreman, R. E., Woodward, O. R. M., Kay, R. G., Goldspink, D. A., Gribble, F. M., & Reimann, F. (2020) · Diabetologia · doi:10.1007/s00125-020-05149-w · Cited by 59
Wharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., Wadden, T. A., & Wilding, J. P. H. (2021) · International Journal of Obesity · doi:10.1038/s41366-020-00733-x · Cited by 58 · cited 1×
“In answering this, it is important to consider that these GLP-1RAs have only been in use for obesity treatment in real-world settings for a limited time, with most available efficacy data currently derived from clinical trials, which tend to over-estimate weight loss effects (84).”
Gao, W., Liu, L., Huh, E., Gbahou, F., Cecon, E., Oshima, M., Houzé, L., Katsonis, P., Hegron, A., Fan, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00889-6 · Cited by 56 · cited 1×
“…genetics study addressed the question of whether genetic variability in GLP-1R impacts people’s susceptibility to obesity and type 2 diabetes, and it identified rare loss-of-function mutations which were associated with increased adiposity in a 200 000-participant UK BioBank cohort (103).”
Park, J. H., Kim, J. Y., Choi, J. H., Park, H. S., Shin, H.-Y., Lee, J. M., Kim, J.-W., Ko, H.-J., Chon, S., Kim, B. K., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00739-z · Cited by 48
Chen, Z., Deng, X., Shi, C., Jing, H., Tian, Y., Zhong, J., Chen, G., Xu, Y., Luo, Y., & Zhu, Y. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178239 · Cited by 48
McDougle, M., Quinn, D., Diepenbroek, C., Singh, A., de la Serre, C., & de Lartigue, G. (2021) · Acta Physiologica · doi:10.1111/apha.13530 · Cited by 42 · cited 1×
“Prolonged consumption of obesogenic diets impairs vagal satiation signaling via multiple pathophysiological mechanisms, including withdrawal of vagal fibers from the NTS (23, 136, 137).”
Obesity and responsibility: Is it time to rethink agency?
Grannell, A., Fallon, F., Al‐Najim, W., & le Roux, C. (2021) · Obesity Reviews · doi:10.1111/obr.13270 · Cited by 41
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021) · Obesity Facts · doi:10.1159/000518325 · Cited by 41
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Santini, S., Vionnet, N., Pasquier, J., Gonzalez‐Rodriguez, E., Fraga, M., Pitteloud, N., & Favre, L. (2023) · Obesity · doi:10.1002/oby.23596 · Cited by 39
GLP-1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract
Card, J. P., Johnson, A. L., Llewellyn‐Smith, I. J., Zheng, H., Anand, R., Brierley, D. I., Trapp, S., & Rinaman, L. (2018) · Journal of Comparative Neurology · doi:10.1002/cne.24482 · Cited by 38
Self-citationA neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretion
Montaner, M., Denom, J., Simon, V., Jiang, W., Holt, M. K., Brierley, D. I., Rouch, C., Foppen, E., Kassis, N., Jarriault, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51076-4 · Cited by 36 · cited 1×
“…to the peripheral source of GLP-1, this peptide is also produced and released from a small population of PPG neurons in the brainstem nucleus tractus solitarius (NTS) and adjacent intermediate reticular nucleus (19–21), along with a small microcircuit population in the olfactory bulb (16, 55, 56).”
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01456-5 · Cited by 35 · cited 3×
“Conversely, the first multicenter real-world cohort study reported an average 13.4% loss (97), comparable to the STEP 1 clinical trial data (79), implying a variable response to semaglutide in different trial and real-world settings.”
InfluentialThiebaud, N., Gribble, F., Reimann, F., Trapp, S., & Fadool, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-51880-9 · Cited by 34
Models of body weight and fatness regulation
Speakman, J. R., & Hall, K. D. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0231 · Cited by 34
Wagner, S., Brierley, D. I., Leeson-Payne, A., Jiang, W., Chianese, R., Lam, B. Y. H., Dowsett, G. K. C., Cristiano, C., Lyons, D., Reimann, F., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101665 · Cited by 32
Self-citationPowell, W., Song, X., Mohamed, Y., Walsh, D., Parks, E. J., McMahon, T. M., Khan, M., & Waitman, L. R. (2023) · Obesity · doi:10.1002/oby.23859 · Cited by 32
Fortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adh0980 · Cited by 32
Genetics of obesity: can an old dog teach us new tricks?
Yeo, G. S. H. (2017) · Diabetologia · doi:10.1007/s00125-016-4187-x · Cited by 31
Kreisler, A. D., & Rinaman, L. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00243.2015 · Cited by 27
Randolph, A. B., Zheng, H., & Rinaman, L. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2063-23.2024 · Cited by 22
Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents
Al Helaili, A., Park, S. J., & Beyak, M. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.045 · Cited by 17 · cited 1×
“Given the role of GLP-1R-expressing VANs in physiological satiation (23, 39), reduced gut GLP-1 secretion and/or decreased vagal sensitivity to GLP-1 could conceivably be part of a vagal contribution to the impaired satiation reported in people living with obesity (135).”
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
Fortin, S. M., Chen, J., & Hayes, M. R. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112870 · Cited by 10
Crabtree, T., Adamson, K., Bickerton, A., Evans, A., Phillips, S., Gallagher, A., Larsen, N., Barnes, D., Dhatariya, K., Field, B. C., et al. (2023) · British Journal of Diabetes · doi:10.15277/bjd.2023.418 · Cited by 6
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Abramof, R. N. (2012) · Yearbook of Medicine · doi:10.1016/s0084-3873(12)00322-7 · Cited by 5
Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina‐Fernandez, J., Dogra, M., Doebley, S. A., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · doi:10.2337/figshare.15125112.v1 · Cited by 5
A neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretionPreprint
Montaner, M., Denom, J., Simon, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.28.555086 · Cited by 3
Endpoints and estimands: understanding trials of weight-loss drugs
Adler, A. I. (2022) · Nature Medicine · doi:10.1038/s41591-022-02032-6 · Cited by 1 · cited 1×
“…intention-to-treat methods such as co-primary endpoints ( ≥ 5% baseline weight loss outcome, and significant placebo-subtracted weight loss) and treatment-focused estimands from all randomized patients, providing average weight loss estimates which better reflect real-world compliance (85).”
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Research works printed but not linked: 2
- Novo Nordisk A/S, Wegovy: Summary of Product Characteristics
- NICE, 2023, Semaglutide for Managing Overweight and Obesity
Cited by
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“The general trajectory of weight loss with initiation of GLP-1 therapy has been well-studied (Table 2) [218–220].”
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Prokopidis, K., Daly, R. M., & Suetta, C. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2025.100652 · Cited by 40
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 43
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
Metadata
- Authors
- Jones, L. A., & Brierley, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Brierley, Daniel I
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2025-01-06
- Volume
- 166
- Issue
- 2
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC11745901
- OpenAlex
- W4406419586
- Cited by
- 43
- References
- 137
- Citations by year
- 2026: 29 · 2025: 14
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrinology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Wellcome Trust (223279/Z/21/Z)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, obesity pharmacotherapy, anti-obesity drugs, food intake regulation, energy intake, central nervous system, neural circuits, gastrointestinal hormones, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Appetite Regulation, Eating, Humans, Obesity, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.